Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vivian Hasbrook

Psychiatry Norman, OK Medical Doctor

NPI 1225101215 CMS profile 9873

900 E Main St, Bldg. 100, Norman, OK 73071

Open in the dashboard

General payments

$11,792

438 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vivian Hasbrook of Norman, OK is reported in the CMS Open Payments database as having received $11,792 across 438 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,328 66
2024 General $2,129 76
2023 General $2,093 80
2022 General $2,043 90
2021 General $1,716 63
2020 General $744 36
2019 General $739 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vivian Hasbrook
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Vivian Hasbrook were reported at $2,328. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Vivian Hasbrook Psychiatry median Middle half National median
2019 $739 $184 $59–$605 $163
2020 $744 $119 $36–$372 $114
2021 $1,716 $143 $43–$576 $132
2022 $2,043 $153 $50–$590 $149
2023 $2,093 $170 $56–$651 $160
2024 $2,129 $179 $57–$673 $164
2025 $2,328 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $2,341 73 payments
  2. Janssen Pharmaceuticals, Inc $1,929 70 payments
  3. Alkermes, Inc. $1,706 56 payments
  4. AbbVie, Inc. $1,469 79 payments
  5. ITI, Inc. $964 36 payments
  6. Otsuka America Pharmaceutical, Inc. $756 23 payments
  7. Indivior Inc. $466 28 payments
  8. Vanda Pharmaceuticals Inc. $455 11 payments
  9. Lundbeck LLC $430 20 payments
  10. E.R. Squibb & Sons, L.L.C. $346 10 payments
  11. Other $932 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,792 438 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $1,684 66 payments
  2. ARISTADA Cns $1,380 52 payments
  3. ARISTADA Cns $1,380 52 payments
  4. ARISTADA Cns $1,232 44 payments
  5. ARISTADA Cns $1,232 44 payments
  6. VRAYLAR $1,165 66 payments
  7. ARISTADA INITIO $1,054 37 payments
  8. CAPLYTA $946 35 payments
  9. AUSTEDO $858 35 payments
  10. LYBALVI $790 26 payments
  11. Other $7,154 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record